
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Until we learn to recognize susceptible infants and avert the immunologic response that results in asthma, we must improve the means by which we treat it.






